Avacta Announces Agreement to Sell Launch Diagnostics and a Corporate Update
LONDON AND PHILADELPHIA, March 07, 2025 (GLOBE NEWSWIRE) — Avacta Therapeutics (AIM: AVCT, 'the Company'), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumor payloads directly to the tumor, announces that it has sold Launch Diagnostics Holdings Limited (“Launch Diagnostics”) and its subsidiaries, its UK-based and largest diagnostics unit, for […]